Skip to main content
Top
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Research article

SnoN expression is differently regulated in microsatellite unstable compared with microsatellite stable colorectal cancers

Authors: June A Chia, Lisa A Simms, Sarah-Jane Cozzi, Joanne Young, Jeremy R Jass, Michael D Walsh, Kevin J Spring, Barbara A Leggett, Vicki LJ Whitehall

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

SnoN is an important regulator of the transforming growth factor beta (TGFβ) signalling pathway and has been shown to exhibit both tumour promotion and suppression activity.

Methods

To further explore the role of this complex molecule in colorectal tumorigenesis, we examined 52 paired normal and tumour colorectal specimens stratified by level of microsatellite instability; 18 with high-level microsatellite instability (MSI-H) and 34 microsatellite stable (MSS). SnoN transcript expression was quantitated by real-time PCR and analysed with respect to clinical indicators of prognosis.

Results

Within the MSI-H subgroup, SnoN was commonly either up-regulated (6/18, 33%) or down-regulated (7/18, 39%). A significantly different distribution of SnoN expression was observed in MSS cancers compared with MSI-H (P ≤ 0.001). Whilst 17/34 (50%) of MSS tumours demonstrated up-regulation, none showed down-regulated expression. Within the MSI-H subgroup, up-regulation was significantly correlated with lack of repeat tract mutation in the TGFβRII gene (P ≤ 0.025), suggesting that SnoN is more frequently up-regulated in the presence of functional TGFβ signalling.

Conclusion

Together these data support the notion that SnoN has both oncogenic and tumour suppressive properties depending on other genetic changes within the tumour, and that the MSI-H pathway of colorectal tumorigenesis presents an excellent model for the study of these opposing functions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Luo K: Ski and SnoN: negative regulators of TGF-b signalling. Current Opinion in Genetics and Development. 2004, 14: 65-70. 10.1016/j.gde.2003.11.003.CrossRefPubMed Luo K: Ski and SnoN: negative regulators of TGF-b signalling. Current Opinion in Genetics and Development. 2004, 14: 65-70. 10.1016/j.gde.2003.11.003.CrossRefPubMed
2.
go back to reference Nagase T, Nomura N, Ishii S: Complex formation between proteins encoded by the ski gene family. Journal of Biological Chemistry. 1993, 268: 13710-13716.PubMed Nagase T, Nomura N, Ishii S: Complex formation between proteins encoded by the ski gene family. Journal of Biological Chemistry. 1993, 268: 13710-13716.PubMed
3.
go back to reference Medrano EE: Repression of TGF-b signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis. Oncogene. 2003, 22: 3123-3129.CrossRefPubMed Medrano EE: Repression of TGF-b signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis. Oncogene. 2003, 22: 3123-3129.CrossRefPubMed
4.
go back to reference Liu X, Sun Y, Weinberg RA, Lodish HF: Ski/Sno and TGF-b signalling. Cytokine Growth Factor Reviews. 2001, 12: 1-8. 10.1016/S1359-6101(00)00031-9.CrossRefPubMed Liu X, Sun Y, Weinberg RA, Lodish HF: Ski/Sno and TGF-b signalling. Cytokine Growth Factor Reviews. 2001, 12: 1-8. 10.1016/S1359-6101(00)00031-9.CrossRefPubMed
5.
go back to reference Heyman HC, Stavnezer E: A carboxyl-terminal region of the Ski oncoprotein mediates homodimerization as well as heterodimerization with the related protein SnoN. Journal of Biological Chemistry. 1994, 269: 26996-27003.PubMed Heyman HC, Stavnezer E: A carboxyl-terminal region of the Ski oncoprotein mediates homodimerization as well as heterodimerization with the related protein SnoN. Journal of Biological Chemistry. 1994, 269: 26996-27003.PubMed
6.
go back to reference Cohen SB, Nicol R, Stavnezer E: A domain necessary for the transforming activity of SnoN is required for specific DNA binding, transcriptional repression and interaction with TAFII110. Oncogene. 1998, 17: 2505-2513. 10.1038/sj.onc.1202177.CrossRefPubMed Cohen SB, Nicol R, Stavnezer E: A domain necessary for the transforming activity of SnoN is required for specific DNA binding, transcriptional repression and interaction with TAFII110. Oncogene. 1998, 17: 2505-2513. 10.1038/sj.onc.1202177.CrossRefPubMed
7.
go back to reference Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K: Negative feedback regulation of TGF-b signaling by the SnoN oncoprotein. Science (Washington DC). 1999, 286: 771-774. 10.1126/science.286.5440.771.CrossRef Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K: Negative feedback regulation of TGF-b signaling by the SnoN oncoprotein. Science (Washington DC). 1999, 286: 771-774. 10.1126/science.286.5440.771.CrossRef
8.
go back to reference Derynck R, Akhurst RJ, Balmain A: TGF-b signaling in tumour suppression and cancer progression. Nature Genetics. 2001, 29: 117-129. 10.1038/ng1001-117.CrossRefPubMed Derynck R, Akhurst RJ, Balmain A: TGF-b signaling in tumour suppression and cancer progression. Nature Genetics. 2001, 29: 117-129. 10.1038/ng1001-117.CrossRefPubMed
9.
go back to reference Shinagawa T, Dong H, Xu D, Maekawa T, Ishii S: The Sno gene, which encodes a component of the histone deactylase complex, acts as a tumour suppressor in mice. EMBO. 2000, 19: 2280-2291. 10.1093/emboj/19.10.2280.CrossRef Shinagawa T, Dong H, Xu D, Maekawa T, Ishii S: The Sno gene, which encodes a component of the histone deactylase complex, acts as a tumour suppressor in mice. EMBO. 2000, 19: 2280-2291. 10.1093/emboj/19.10.2280.CrossRef
10.
go back to reference Sarker KP, Wilson SM, Bonni S: SnoN is a cell type-specific mediator of transforming growth factor-beta responses. The Journal of Biological Chemistry. 2005, 280: 13037-13046. 10.1074/jbc.M409367200.CrossRefPubMed Sarker KP, Wilson SM, Bonni S: SnoN is a cell type-specific mediator of transforming growth factor-beta responses. The Journal of Biological Chemistry. 2005, 280: 13037-13046. 10.1074/jbc.M409367200.CrossRefPubMed
11.
go back to reference Buess M, Terracciano L, Reuter J, Ballabeni P, Boulay JL, Laffer U, Metzger U, Herrmann R, Rochiltz CF: Amplification of SKI is a prognostic marker in early colorectal cancer. Neoplasia. 2004, 6: 207-212. 10.1593/neo.03442.CrossRefPubMedPubMedCentral Buess M, Terracciano L, Reuter J, Ballabeni P, Boulay JL, Laffer U, Metzger U, Herrmann R, Rochiltz CF: Amplification of SKI is a prognostic marker in early colorectal cancer. Neoplasia. 2004, 6: 207-212. 10.1593/neo.03442.CrossRefPubMedPubMedCentral
12.
go back to reference Zhang F, Lundin M, Ristimaki A, Heikkila P, Lundin J, Isola J, Joensuu H, Laiho M: Ski-related novel protein N (SnoN), a negative controller of Transforming Growth Factor-b signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Research. 2003, 63: 5005-5010.PubMed Zhang F, Lundin M, Ristimaki A, Heikkila P, Lundin J, Isola J, Joensuu H, Laiho M: Ski-related novel protein N (SnoN), a negative controller of Transforming Growth Factor-b signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Research. 2003, 63: 5005-5010.PubMed
13.
go back to reference Fukuchi M, Nakajima M, Fukai Y, Miyazaki T, Masuda N, Sohda M, Manda R, Tsukada K, Kato H, Kuwano H: Increased expression of c-Ski as a co-repressor in transforming growth factor-b signaling correlates with progression of esophageal squamous cell carcinoma. International Journal of Cancer. 2004, 108: 818-824. 10.1002/ijc.11651.CrossRefPubMed Fukuchi M, Nakajima M, Fukai Y, Miyazaki T, Masuda N, Sohda M, Manda R, Tsukada K, Kato H, Kuwano H: Increased expression of c-Ski as a co-repressor in transforming growth factor-b signaling correlates with progression of esophageal squamous cell carcinoma. International Journal of Cancer. 2004, 108: 818-824. 10.1002/ijc.11651.CrossRefPubMed
14.
go back to reference Smith G, Carey FA, Beattie J, Wilkie MJV, Lightfoot TJ, Coxhead J, Garner RC, Steele RJC, Wolf CR: Mutations in APC, Kirsten-ras and p53 - alternative genetic pathways to colorectal cancer. Proceedings of the National Academy of Science, USA. 2002, 99: 9433-9438. 10.1073/pnas.122612899.CrossRef Smith G, Carey FA, Beattie J, Wilkie MJV, Lightfoot TJ, Coxhead J, Garner RC, Steele RJC, Wolf CR: Mutations in APC, Kirsten-ras and p53 - alternative genetic pathways to colorectal cancer. Proceedings of the National Academy of Science, USA. 2002, 99: 9433-9438. 10.1073/pnas.122612899.CrossRef
15.
go back to reference Chang SC, Lin JK, Yang SH, Wang HS, Li AF, Chi CW: Relationship between genetic alterations and prognosis in sporadic colorectal cancer. International Journal of Cancer. 2006, 118: 1721-1727. 10.1002/ijc.21563.CrossRefPubMed Chang SC, Lin JK, Yang SH, Wang HS, Li AF, Chi CW: Relationship between genetic alterations and prognosis in sporadic colorectal cancer. International Journal of Cancer. 2006, 118: 1721-1727. 10.1002/ijc.21563.CrossRefPubMed
16.
go back to reference Edmonston TB, Cuesta KH, Burkholder S, Barusevicius A, Rose D, Kovatich AJ, Boman B, Fry R, Fishel R, Palazzo JP: Colorectal carcinomas with high microsatellite instability: defining a distinct immunologic and molecular entity with respect to prognostic markers. Human Pathology. 2000, 31: 1506-1514. 10.1053/hupa.2000.20383.CrossRefPubMed Edmonston TB, Cuesta KH, Burkholder S, Barusevicius A, Rose D, Kovatich AJ, Boman B, Fry R, Fishel R, Palazzo JP: Colorectal carcinomas with high microsatellite instability: defining a distinct immunologic and molecular entity with respect to prognostic markers. Human Pathology. 2000, 31: 1506-1514. 10.1053/hupa.2000.20383.CrossRefPubMed
17.
go back to reference Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S: A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Research. 1998, 58: 5248-5257.PubMed Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S: A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Research. 1998, 58: 5248-5257.PubMed
18.
go back to reference Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research. 2001, 29: 2002-2007. 10.1093/nar/29.9.e45.CrossRef Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research. 2001, 29: 2002-2007. 10.1093/nar/29.9.e45.CrossRef
19.
go back to reference Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang C, Fleming J, Tavana D, Frenkel E, Becerra C: Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clinical Cancer Research. 2003, 9: 931-946.PubMed Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang C, Fleming J, Tavana D, Frenkel E, Becerra C: Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clinical Cancer Research. 2003, 9: 931-946.PubMed
20.
go back to reference Ni HM, Leong A, Cheong D, Hooi S: Expression of CD44 variants in colorectal carcinoma quantified by real-time reverse transcriptase-polymerase chain reaction. Journal of Laboratory Clinical Medicine. 2002, 139: 59-65. 10.1067/mlc.2002.120425.CrossRefPubMed Ni HM, Leong A, Cheong D, Hooi S: Expression of CD44 variants in colorectal carcinoma quantified by real-time reverse transcriptase-polymerase chain reaction. Journal of Laboratory Clinical Medicine. 2002, 139: 59-65. 10.1067/mlc.2002.120425.CrossRefPubMed
21.
go back to reference Newland RC, Chapuis PH, Smyth EJ: The prognostic value of substaging colorectal carcinoma. Cancer. 1987, 60: 852-857. 10.1002/1097-0142(19870815)60:4<852::AID-CNCR2820600422>3.0.CO;2-5.CrossRefPubMed Newland RC, Chapuis PH, Smyth EJ: The prognostic value of substaging colorectal carcinoma. Cancer. 1987, 60: 852-857. 10.1002/1097-0142(19870815)60:4<852::AID-CNCR2820600422>3.0.CO;2-5.CrossRefPubMed
22.
go back to reference Wood DA: Clinical staging and end results classification: TNM system of clinical classification as applicable to carcinoma of the colon and rectum. Cancer. 1971, 28: 109-114. 10.1002/1097-0142(197107)28:1<109::AID-CNCR2820280120>3.0.CO;2-C.CrossRefPubMed Wood DA: Clinical staging and end results classification: TNM system of clinical classification as applicable to carcinoma of the colon and rectum. Cancer. 1971, 28: 109-114. 10.1002/1097-0142(197107)28:1<109::AID-CNCR2820280120>3.0.CO;2-C.CrossRefPubMed
23.
go back to reference Web Chi Square Calculator [http://www.georgetown.edu/faculty/ballc/webtools/web_chi.html]. Web Chi Square Calculator [http://​www.​georgetown.​edu/​faculty/​ballc/​webtools/​web_​chi.​html].
24.
go back to reference GraphPad Prism version 4.00 for Windows, GraphPad Software, San Diego California USA [www.graphpad.com]. GraphPad Prism version 4.00 for Windows, GraphPad Software, San Diego California USA [www.graphpad.com].
25.
go back to reference He J, Tegen SB, Krawitz AR, Martin GS, Luo K: The transforming activity of Ski and SnoN is dependent on their ability to repress the activity of Smad proteins. Journal of Biological Chemistry. 2003, 278: 30540-30547. 10.1074/jbc.M304016200.CrossRefPubMed He J, Tegen SB, Krawitz AR, Martin GS, Luo K: The transforming activity of Ski and SnoN is dependent on their ability to repress the activity of Smad proteins. Journal of Biological Chemistry. 2003, 278: 30540-30547. 10.1074/jbc.M304016200.CrossRefPubMed
26.
go back to reference Siegel PM, Massague J: Cytostatic and apoptotic actins of TGF-beta in homeostasis and cancer. Nature Reviews. 2003, 3: 807-820. 10.1038/nrc1208.PubMed Siegel PM, Massague J: Cytostatic and apoptotic actins of TGF-beta in homeostasis and cancer. Nature Reviews. 2003, 3: 807-820. 10.1038/nrc1208.PubMed
27.
go back to reference Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B: Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Research. 1995, 55: 5548-5550.PubMed Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B: Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Research. 1995, 55: 5548-5550.PubMed
28.
go back to reference Takenoshita S, Tani M, Nagashima M, Hagiwara K, Bennett WP, Yokota J, Harris CC: Mutation analysis of coding sequences of the entire transforming growth factor β type II receptor gene in sporadic human colon cancer using genomic DNA and intron primers. Oncogene. 1997, 14: 1255-1258. 10.1038/sj.onc.1200938.CrossRefPubMed Takenoshita S, Tani M, Nagashima M, Hagiwara K, Bennett WP, Yokota J, Harris CC: Mutation analysis of coding sequences of the entire transforming growth factor β type II receptor gene in sporadic human colon cancer using genomic DNA and intron primers. Oncogene. 1997, 14: 1255-1258. 10.1038/sj.onc.1200938.CrossRefPubMed
29.
go back to reference Wright CM, Dent OF, Barker M, Newland RC, Chapuis H, Bokey EL, Young JP, Leggett BA, Jass JR, Macdonald GA: Prognositc significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. British Journal of Surgery. 2000, 87: 1197-1202. 10.1046/j.1365-2168.2000.01508.x.CrossRefPubMed Wright CM, Dent OF, Barker M, Newland RC, Chapuis H, Bokey EL, Young JP, Leggett BA, Jass JR, Macdonald GA: Prognositc significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. British Journal of Surgery. 2000, 87: 1197-1202. 10.1046/j.1365-2168.2000.01508.x.CrossRefPubMed
Metadata
Title
SnoN expression is differently regulated in microsatellite unstable compared with microsatellite stable colorectal cancers
Authors
June A Chia
Lisa A Simms
Sarah-Jane Cozzi
Joanne Young
Jeremy R Jass
Michael D Walsh
Kevin J Spring
Barbara A Leggett
Vicki LJ Whitehall
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-252

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine